After over 1000 adverse event reports, several consumer watchdog groups have urged diabetics to avoid using Actos or its generic equivalent. Many have espoused that actos use may not be worth the associated health risks. A group by the name of “Consumer Reports” noted that Actos should only be used as a “last resort” diabetes… Read More
According to a recent review of FDA adverse event reports, the FDA has received over 1000 reports from individuals reporting unexplained diagnoses of bladder cancer after Actos use. This comes after several prominent scientific reports linked Actos use to an increased likelihood of developing bladder cancer. The institute for Safe Medication Practices (ISMP) recently analyzed… Read More
According to a new study published in the British Medicine Journal which compared healthy people with patients diagnosed with bladder cancer, Actos use has been associated with an 83% increased risk of bladder cancer and a 200% increased risk of bladder cancer if Actos is used for more than 2 years. Previous research indicated that… Read More
MDL Consolidation to eliminate duplicative discovery, prevent inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary Actos (pioglitazone) was marketed by Takeda Pharmaceuticals America Inc. and Eli Lilly and Co. in 1999 for the treatment of Type II diabetes. During a study conducted by Kaiser Permanente, it was demonstrated… Read More
